A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer

NCT00073151 — Phase 2, Completed, 30 participants, Abbott
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Phase II Study of ABT-751 in Patients With Non-Small Cell Lung Cancer Refractory to Taxane Regimens

RegistryNCT00073151
StatusCompleted
PhasePhase 2
Study typeInterventional; non randomized, single group, masking: none, treatment
Enrollment30 (Estimated)
SponsorAbbott (Industry)
ConditionsNon-Small Cell Lung Cancer
InterventionsABT-751 (Drug)
Datesstart 2003-09-01, completion 2006-01-01, first posted 2003-11-18, last updated 2007-11-29
Locations17 sites in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Non-Small Cell Lung Cancer All trials of ABT-751

-Summary

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Expand all sections  ·  Collapse all

+Arms and interventions

  • ABT-751 (Drug)

+Outcome measures

Primary outcomes

  • Objective Response Rate in subjects with NSCLC [1 year]

Secondary outcomes

  • Time to Tumor Progression (TTP) [1 year]
  • Survival [2 years]
  • Toxicities associated with treatment administration [1 year]

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria

* Stage IIIB or IV non-small cell lung cancer.
* Recurrent tumor following treatment with paclitaxel or docetaxel.
* Able to tolerate normal activities of daily living.
* Adequate bone marrow, kidney and liver function.

Exclusion Criteria

* Pregnant or breast feeding.
* Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
* CNS metastasis.

+Locations (17)

FacilityCityCountryStatus
Oncology Hematology Group of South FloridaMiami, FloridaUnited States
Florida Cancer InstituteNew Port Richey, FloridaUnited States
University of Chicago Medical CenterChicago, IllinoisUnited States
University of Maryland Greenbaum Cancer CenterBaltimore, MarylandUnited States
Oncology & Hematology Associates of Kansas City, PAKansas City, MissouriUnited States
Washington University School of MedicineSt Louis, MissouriUnited States
Albany Regional Cancer CenterAlbany, New YorkUnited States
Raleigh Hematology OncologyCary, North CarolinaUnited States
Dayton Oncology and HematologyKettering, OhioUnited States
Cancer Care AssociatesOklahoma City, OklahomaUnited States
Cancer Centers of the CarolinasGreenville, South CarolinaUnited States
West Cancer ClinicMemphis, TennesseeUnited States
Texas OncologyDallas, TexasUnited States
Texas OncologyFort Worth, TexasUnited States
Cancer Care NorthwestSpokane, WashingtonUnited States
Northwest Cancer SpecialistsVancouver, WashingtonUnited States
University of Wisconsin Comprehensive Cancer CenterMadison, WisconsinUnited States

+Investigators